Return to homepagePandemic Pact

COVID-19: CCR1 antagonist for therapy of hospitalized COVID-19 patients (CATCOVID) - Leipzig study centre within the clinical trial phase II

  • Funded by Federal Ministry of Research, Technology and Space (BMFTR)
  • Total publications:0 publications

Grant number: 03LW0009

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021
    2023

  • Known Financial Commitments (USD)

    $219,015.02

  • Funder

    Federal Ministry of Research, Technology and Space (BMFTR)

  • Principal Investigator

    N/A

  • Research Location

    Germany

  • Lead Research Institution

    Universität Leipzig

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

N/A